The All India Institute of Medical Sciences (AIIMS) has conducted India’s first clinical trial of the Supernova stent, marking a major milestone in the field of stroke care and advanced medical research in the country. The trial represents a significant step towards improving treatment options for patients suffering from acute ischemic stroke, one of the leading causes of death and long-term disability.
According to AIIMS officials, the Supernova stent is a next-generation device designed to remove blood clots from blocked brain arteries and rapidly restore blood flow, thereby reducing brain damage and improving patient outcomes. The clinical trial assessed the safety, efficacy and performance of the stent in carefully selected patients under controlled medical conditions.
Medical experts involved in the study said the successful completion of the trial demonstrates India’s growing capability to conduct high-quality clinical research involving advanced medical devices. They noted that timely intervention using such innovative technologies can significantly enhance survival rates and recovery prospects for stroke patients.
AIIMS emphasised that the trial reflects its commitment to advancing patient care through research, innovation and adoption of cutting-edge technologies. Officials added that indigenous and early-stage clinical trials of advanced devices like the Supernova stent could help make modern stroke treatment more accessible and affordable in the future.
The achievement also highlights India’s progress in strengthening its healthcare and research ecosystem, with institutions like AIIMS playing a leading role in driving medical innovation for public benefit.
